Clinical Evaluation of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 6
- 主要终点
- Percentage of Participants With Completion of Imaging With the NUVISION NAV Ultrasound Catheter Without Resort to Non-study Mapping Catheter
研究概览
简要总结
The purpose of this study is to assess the performance and safety of using the investigational catheter.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with and candidate for clinically-indicated cardiac ablation procedure for the management of ventricular tachycardia, premature ventricular complex, scar-related atrial tachycardia or atrial fibrillation (participants having undergone a previous ablation procedure may be included)
- •Signed participants Informed Consent Form (ICF)
- •Able and willing to comply with all pre-, post-, and follow-up testing and requirements
排除标准
- •Structural heart defect which can only be repaired by cardiac surgery
- •Pericarditis within 6 months
- •Left ventricular ejection fraction (LVEF) less than or equal to (<=) 25 percent (%) for ventricular tachycardia (VT) participants
- •LVEF <= 40% for participants with atrial arrhythmia
- •History of chronic gastro-intestinal medical problems involving the esophagus, stomach and/or untreated acid reflux
- •History of abnormal bleeding and/or clotting disorder
- •Clinically significant infection or sepsis
- •History of stroke or transient ischemic attack (TIA) within the past 6 months of enrollment
- •Uncontrolled heart failure or New York Heart Association (NYHA) function class IV
- •Implanted with a pacemaker or intracardiac cardiac defibrillator within the past 6 weeks (42 days)
- •Implanted with a mechanical valve
- •Diagnosed atrial or ventricular myxoma, interatrial baffle or patch, tumor or other abnormality that precludes catheter introduction or manipulation
- •Any of the following within 6 months of enrollment: major surgery except for the index procedure, myocardial infarction, unstable angina, percutaneous coronary intervention
- •Participants with any other significant uncontrolled or unstable medical condition (such as uncontrolled bradyarrhythmia's, ventricular arrhythmias, hyperthyroidism, or significant coagulation disorder)
- •Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study
- •Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of childbearing age and plan on becoming pregnant during the course of the clinical investigation
- •Categorized as vulnerable population and requires special treatment with respect to safeguards of well-being
- •Concurrent enrollment in an investigational study evaluating another device or drug
结局指标
主要结局
Percentage of Participants With Completion of Imaging With the NUVISION NAV Ultrasound Catheter Without Resort to Non-study Mapping Catheter
时间窗: At Day 1
Percentage of participants with completion of imaging with the NUVISION NAV ultrasound catheter without resort to non-study mapping catheter were reported.
Number of Participants With Serious Adverse Events (SAEs) Within 7 Days of Index Procedure Related to the NUVISION NAV Ultrasound Catheter
时间窗: From day of index procedure (Day 1) up to 7 days
Number of participants with SAEs within 7 days of index procedure related to the NUVISION NAV ultrasound catheter were reported. An AE was any untoward medical experience (sign, symptom, illness, abnormal laboratory value, or other medical event) occurring to a participant during the course of the study whether or not related to the investigational device. SAE was any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, was life-threatening experience, a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.
次要结局
- Physician Assessment of Deployment, Maneuverability and Navigational Features With the NUVISION NAV Ultrasound Catheter During the Study Procedures(Day 1)
- Physician Assessment of Imaging Quality Acquired With the NUVISION NAV Ultrasound Catheter During the Study Procedures(Day 1)
- Physicians Overall Feedback on the NUVISION NAV Ultrasound Catheter During the Study Procedures(Day 1)
- Number of Serious Adverse Events (SAEs) Excluding NUVISION NAV Ultrasound Catheter Related SAE Within 7 Days of Index Procedure(From day of index procedure (Day 1) up to 7 days)
- Number of Participants With Non-serious Adverse Events Within 7 Days of Index Procedure Related to the NUVISION NAV Ultrasound Catheter(From day of index procedure (Day 1) up to 7 days)